NEW YORK (GenomeWeb News) – Varian today said that its shareholders have approved the firm's merger agreement with Agilent Technologies.

The deal, under which Agilent will acquire Varian for $52 per share in cash — for a total transaction value of around $1.5 billion — was announced in late July.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.